SCHEMBL20119610

SCHEMBL20119610

Clc1nc(NCc2ccccn2)c2cc[nH]c2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.51
IGF1R P08069 1/20 0.51
PIM1 P11309 1/20 0.51
SRC P12931 1/20 0.51
CSNK2A2 P19784 1/20 0.51
KCNA5 P22460 1/20 0.51
JAK1 P23458 1/20 0.51
CCNE1 P24864 1/20 0.51
CDK2 P24941 1/20 0.51
TYK2 P29597 1/20 0.51
FLT4 P35916 1/20 0.51
FLT3 P36888 1/20 0.51
MAP3K8 P41279 1/20 0.51
CSNK1A1 P48729 1/20 0.51
GSK3B P49841 1/20 0.51
JAK3 P52333 1/20 0.51
PLK1 P53350 1/20 0.51
CSNK2A1 P68400 1/20 0.51
CDK5 Q00535 1/20 0.51
BTK Q06187 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119845 0.85 APP (0.44) JAK2IGF1RPIM1SRCCSNK2A2
SCHEMBL20119640 0.83 KCNH3 (0.40) JAK2IGF1RPIM1SRCCSNK2A2
SCHEMBL20119420 0.83 PDE5A (0.38) JAK2IGF1RPIM1SRCCSNK2A2
SCHEMBL20119612 0.83 EGFR (0.38) JAK2IGF1RPIM1SRCCSNK2A2
SCHEMBL20119777 0.81 APP (0.38) JAK2IGF1RPIM1SRCCSNK2A2
SCHEMBL4089465 0.80 PDE5A (0.69) JAK2IGF1RPIM1SRCCSNK2A2
SCHEMBL20119459 0.79 RECQL (0.51) JAK2IGF1RPIM1SRCCSNK2A2
SCHEMBL20119891 0.79 APP (0.48) JAK2IGF1RPIM1SRCCSNK2A2
SCHEMBL20119509 0.79 DYRK3 (0.40) JAK2IGF1RPIM1SRCCSNK2A2
SCHEMBL20119943 0.78 PIM1 (0.39) JAK2PIM1JAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 JAK2 4665/4885IGF1R 4492/4885PIM1 3958/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 JAK2 4665/4885IGF1R 4492/4885PIM1 3958/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 JAK2 4665/4885IGF1R 4492/4885PIM1 3958/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 JAK2 4665/4885IGF1R 4492/4885PIM1 3958/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 JAK2 4665/4885IGF1R 4492/4885PIM1 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.